| Literature DB >> 26796783 |
Annemarijn C Prins-van Ginkel1, Guy A M Berbers1, Lucienne H Grundeken1, Irina Tcherniaeva1, Jelle I Wittenberns1, Karin Elberse1, Liesbeth Mollema1, Hester E de Melker1, Mirjam J Knol1.
Abstract
INTRODUCTION: Introduction of pneumococcal conjugate vaccines (PCVs) for infants decreased overall invasive pneumococcal disease (IPD), while non-vaccine serotype IPD increased. To fully understand this serotype replacement, knowledge about serotype dynamics in the pre-vaccine era is needed. In addition to IPD surveillance and carriage studies, the serotype replacement can be investigated by serosurveillance studies. The current study compared the results of two Dutch serosurveillance studies conducted in 1995-1996 (PIENTER1) and 2006-2007 (PIENTER2).Entities:
Mesh:
Substances:
Year: 2016 PMID: 26796783 PMCID: PMC4721864 DOI: 10.1371/journal.pone.0147437
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Flowchart of the PIENTER1 study population.
The number of persons invited to participate in the PIENTER1 study and the number actually included in the GMC ratio (dashed line) and the determinant calculations (dotted line).
Fig 2Flowchart of the PIENTER2 study population.
The number of persons invited to participate in the PIENTER2 study and the number of participants actually included in the GMC ratio (dashed line) and the determinant calculations (dotted line). * Participants not vaccinated with a pneumococcal conjugate vaccine (PCV), participants vaccinated with other (non-pneumococcal) vaccines were not excluded.
Geometric mean antibody concentration (GMC) ratios of children aged 0–3 years PIENTER1 and PIENTER2 based on univariable and multivariable generalized estimating equation analysis.
| PIENTER1 | PIENTER2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Determinants | Crude GMC ratio [95%CI] | P-value interaction- term crude analysis | Adjusted GMC ratio [95% CI] | P-value interaction-term adjusted analysis | Range of GMC ratio’s | Crude GMC ratio [95%CI] | P-value interaction- term crude analysis | Adjusted GMC ratio [95% CI] | P-value interaction-term adjusted analysis | Range of GMC ratio’s |
| NA | NA | NA | NA | NA | 0.005 | 0.087 | ||||
| Many contact (>5persons) | 1.11[0.9–1.4] | 0.91–1.61 | ||||||||
| Average contact (1–4 persons) | 1.10[0.9–1.3] | 0.95–1.25 | ||||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.166 | 0.629 | ||||
| Many contact (>5 persons) | 1.38[1.0–1.9] | 0.95[0.7–1.3] | 0.75–1.59 | |||||||
| Average contact (1–4 persons) | 0.98[0.8–1.2] | 0.83–1.22 | ||||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.541 | 0.595 | ||||
| Many contact (>5 persons) | 1.21[0.9–1.6] | 0.94[0.8–1.2] | 0.74–1.18 | |||||||
| Average contact (1–4 persons) | 1.12[0.9–1.4] | 0.94–1.31 | ||||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.131 | 0.057 | ||||
| Contact | 1.11[0.9–1.4] | 0.98[0.8–1.2] | 0.83–1.15 | |||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.721 | 0.735 | ||||
| Participant and cohabitant ≤ 4 years | 0.88[0.8–1.1] | 0.89[0.8–1.0] | 0.83–0.98 | |||||||
| Only participant ≤ 4years | Ref. | Ref. | Ref. | |||||||
| <0.001 | <0.001 | 0.212 | ||||||||
| >2 days | 1.34[0.9–2.0] | 0.84–2.15 | 1.22[0.9–1.6] | 0.85–1.71 | ||||||
| 0.5–2 days | 0.90–2.23 | 1.14[1.0–1.4] | 0.88–1.50 | |||||||
| No attendance | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.335 | 0.170 | 0.046 | ||||||||
| 1–4 persons | 0.84[0.7–1.0] | 0.68–1.07 | 0.60–0.91 | |||||||
| >4 persons | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.953 | 0.863 | 0.367 | 0.283 | |||||||
| Male | 0.86[0.7–1.0] | 0.75–1.00 | 0.96[0.8–1.1] | 1.00[0.9–1.2] | 0.87–1.21 | |||||
| Female | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| <0.001 | 1.23–1.71 | <0.001 | 1.31–1.99 | |||||||
| <0.001 | 0.292 | 0.664 | ||||||||
| Non-Western | 1.12[0.7–1.7] | 1.04[0.7–1.6] | 0.67–2.44 | 1.20[0.9–1.6] | 1.02–1.67 | |||||
| Western | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| <0.001 | 0.075 | 0.025 | 0.054 | |||||||
| Low | 1.01[0.5–1.9] | 0.50–1.86 | 1.32[1.0–1.8] | 0.93[0.7–1.3] | 0.61–2.00 | |||||
| Middle | 0.99[0.8–1.2] | 1.08[0.9–1.3] | 0.88–1.28 | 0.94[0.8–1.1] | 0.98[0.8–1.2] | 0.86–1.09 | ||||
| High | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.131 | 0.072 | 0.053 | 0.084 | |||||||
| Yes | 0.93[0.7–1.3] | 0.84[0.7–1.1] | 0.61–1.59 | 0.86[0.5–1.4] | 0.82[0.5–1.3] | 0.63–1.03 | ||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.735 | 0.816 | <0.001 | ||||||||
| Low vaccination coverage sample | 0.54–0.85 | 0.45–0.82 | ||||||||
| National sample | Ref. | Ref. | Ref. | Ref. | Ref. | |||||
| 0.001 | 0.235 | 0.112 | ||||||||
| Very high | 1.24[0.9–1.7] | 0.57–1.96 | 1.08[0.8–1.4] | 0.77[0.6–1.0] | 0.66–0.93 | |||||
| High | 1.40[0.9–2.2] | 0.77[0.5–1.2] | 0.45–1.80 | 1.11[0.9–1.4] | 0.94[0.7–1.2] | 0.79–1.22 | ||||
| Moderate high | 0.97[0.8–1.3] | 0.62–1.00 | 0.97[0.7–1.3] | 0.82[0.6–1.1] | 0.62–1.15 | |||||
| Low | 0.97[0.8–1.2] | 0.85[0.7–1.0] | 0.58–1.15 | 0.83[0.7–1.1] | 1.03[0.9–1.3] | 0.79–1.23 | ||||
| Very low | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
Bold indicates a p-value of <0.05. NA: Not available. Ref.: Reference.
Geometric mean antibody concentration (GMC) ratios of elderly aged ≥65 years PIENTER1 and PIENTER2 based on univariable and multivariable generalized estimating equation analysis.
| PIENTER1 | PIENTER2 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Determinants | Crude GMC ratio [95%CI] | P-value interaction- term crude analysis | Adjusted GMC ratio [95% CI] | P-value interaction-term adjusted analysis | Range of GMC ratio’s | Crude GMC ratio [95%CI] | P-value interaction- term crude analysis | Adjusted GMC ratio [95% CI] | P-value interaction-term adjusted analysis | Range of GMC ratio’s |
| NA | NA | NA | NA | NA | 0.375 | 0.343 | ||||
| Contact | 1.13[1.0–1.3] | 1.05[0.9–1.3] | 0.89–1.32 | |||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.465 | 0.507 | ||||
| Contact | 1.14[1.0–1.3] | 0.98–1.30 | ||||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.429 | 0.125 | ||||
| Contact | 0.99[0.9–1.1] | 0.96[0.9–1.1] | 0.87–1.09 | |||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.567 | 0.527 | ||||
| Contact | 0.97[0.9–1.1] | 0.99[0.9–1.1] | 0.88–1.08 | |||||||
| No contact | Ref. | Ref. | Ref. | |||||||
| NA | NA | NA | NA | NA | 0.138 | 0.275 | ||||
| Yes | 1.05[0.8–1.3] | 1.05[0.8–1.3] | 0.88–1.35 | |||||||
| No | Ref. | Ref. | Ref. | |||||||
| 0.005 | 0.941 | 0.924 | ||||||||
| >2 persons | 1.06[0.7–1.7] | 1.01[0.7–1.6] | 0.73–1.85 | 1.16[1.0–1.4] | 1.09[0.9–1.3] | 0.97–1.30 | ||||
| 1–2 persons | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.558 | 0.814 | 0.774 | 0.853 | |||||||
| Male | 1.06[0.9–1.3] | 1.08[0.9–1.3] | 0.83–1.33 | 1.09–1.35 | ||||||
| Female | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 1.01[1.0–1.0] | 0.402 | 1.01[1.0–1.0] | 0.401 | 0.98–1.03 | 0.313 | 0.326 | 0.97–1.00 | |||
| <0.001 | 0.004 | |||||||||
| Non-Western | 0.08–2.00 | 1.15[1.0–1.4] | 1.07[0.9–1.3] | 0.81–1.54 | ||||||
| Western | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.012 | 0.129 | 0.436 | 0.336 | |||||||
| Low | 1.11–3.12 | 1.13–1.57 | ||||||||
| Middle | 1.03–2.62 | 1.11[1.0–1.3] | 1.14[1.0–1.3] | 1.04–1.28 | ||||||
| High | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.740 | 0.636 | 0.015 | ||||||||
| Yes | 1.18–1.93 | 0.96[0.8–1.2] | 0.95[0.8–1.2] | 0.64–1.19 | ||||||
| No | Ref. | Ref. | Ref. | Ref. | Ref. | Ref | ||||
| 0.644 | 0.700 | 0.231 | 0.208 | |||||||
| Low vaccination coverage sample | 1.09[0.9–1.3] | 0.59–0.89 | 1.00[0.9–1.1] | 1.00[0.8–1.2] | 0.91–1.17 | |||||
| National sample | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
| 0.008 | 0.678 | 0.763 | ||||||||
| Very high | 0.32–0.96 | 0.96[0.8–1.1] | 0.99[0.8–1.2] | 0.87–1.14 | ||||||
| High | 0.24–0.64 | 1.10[1.0–1.3] | 1.14[1.0–1.4] | 1.05–1.24 | ||||||
| Moderate high | 0.42–0.73 | 0.98[0.8–1.2] | 1.03[0.8–1.3] | 0.85–1.20 | ||||||
| Low | 0.52–0.82 | 1.03[0.9–1.2] | 1.07[0.9–1.3] | 0.99–1.18 | ||||||
| Very low | Ref. | Ref. | Ref. | Ref. | Ref. | Ref. | ||||
Bold indicates a p-value of <0.05. NA: not applicable. Ref.: Reference
* This estimate was calculated using an unstructured working correlation structure.
Fig 3Weighted geometric mean concentration (GMC) ratios per serotype of PIENTER2 versus PIENTER1 with corresponding 95% confidence intervals.
Fig 4Weighted geometric mean concentrations (GMCs) with 95% confidence intervals of the national sample of PIENTER1 and PIENTER2 per serotype per age group.
Fig 5Weighted geometric mean concentrations (GMCs) with 95% confidence intervals of the low vaccination coverage sample of PIENTER1 and PIENTER2 per serotype.